Option Care Health, Inc. (NASDAQ:OPCH) Director Harry M. Jansen Kraemer, Jr. Purchases 43,000 Shares

Option Care Health, Inc. (NASDAQ:OPCH) Director Harry M. Jansen Kraemer, Jr. bought 43,000 shares of the firm’s stock in a transaction on Friday, November 8th. The shares were purchased at an average price of $22.54 per share, for a total transaction of $969,220.00. Following the purchase, the director now owns 326,334 shares in the company, valued at $7,355,568.36. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.

Option Care Health Stock Down 2.9 %

OPCH opened at $22.18 on Thursday. The business’s fifty day simple moving average is $29.24 and its 200 day simple moving average is $29.54. The company has a quick ratio of 1.32, a current ratio of 1.73 and a debt-to-equity ratio of 0.77. The firm has a market cap of $3.77 billion, a P/E ratio of 18.64, a PEG ratio of 2.37 and a beta of 1.32. Option Care Health, Inc. has a 52 week low of $22.11 and a 52 week high of $34.63.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on OPCH shares. Truist Financial reduced their price objective on shares of Option Care Health from $41.00 to $34.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Bank of America downgraded Option Care Health from a “buy” rating to a “neutral” rating and dropped their price target for the company from $43.00 to $29.00 in a research note on Wednesday, October 30th. Jefferies Financial Group downgraded Option Care Health from a “buy” rating to a “hold” rating and decreased their price target for the company from $38.00 to $26.00 in a report on Thursday, October 31st. JMP Securities upped their target price on Option Care Health from $36.00 to $37.00 and gave the stock a “market outperform” rating in a research note on Monday, September 30th. Finally, The Goldman Sachs Group lowered Option Care Health from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $38.00 to $27.00 in a research note on Monday, November 4th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.83.

Institutional Trading of Option Care Health

Large investors have recently bought and sold shares of the company. Harbor Capital Advisors Inc. increased its position in shares of Option Care Health by 317.9% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 96,375 shares of the company’s stock worth $2,670,000 after purchasing an additional 73,312 shares during the last quarter. Comerica Bank grew its position in shares of Option Care Health by 6.5% in the 1st quarter. Comerica Bank now owns 760,915 shares of the company’s stock worth $25,521,000 after acquiring an additional 46,639 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of Option Care Health by 182.9% during the first quarter. Janus Henderson Group PLC now owns 227,135 shares of the company’s stock worth $7,617,000 after purchasing an additional 146,837 shares during the period. Edgestream Partners L.P. lifted its holdings in Option Care Health by 96.8% in the second quarter. Edgestream Partners L.P. now owns 351,476 shares of the company’s stock worth $9,736,000 after acquiring an additional 172,845 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in Option Care Health in the second quarter valued at approximately $973,000. Institutional investors and hedge funds own 98.05% of the company’s stock.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.